profile

Floris from Blossom

The Bloom 9 - A non-hallucinogenic LSD analogue

Published about 1 year ago • 3 min read

This week a barrage of psychedelic research was published. We cover seven new articles in our database, of which the first three are featured here.

The non-hallucinogenic trip continues with another mouse/cell study showing a favourable profile over LSD. In the database you will also find a paper covering positive results of psilocybin on alcohol consumption, in male mice.

We then cover how people self-treated with psilocybin and LSD. This data is captured in the Global Drug Survey (2020), and shows generally positive outcomes (though 23% report negative effects too).

Finally, we dive into the association between mystical experiences and positive outcomes in an excellent review by Samuli Kangaslampi. He finds an association, yet also finds this for insight and emotional breakthrough.

Floris - Founder of Blossom

1 A non-hallucinogenic LSD analog with therapeutic potential for mood disorders

This mice and cell study of the non-hallucinogenic LSD analogue 2-bromo-LSD (2-Br-LSD) found it to be a partial agonist at the 5-HT2A receptor but it doesn't activate the 5-HT2B receptor associated with cardiac valvulopathy (disease of heart valves). It also does not induce tolerance and has been shown to promote neuronal structural plasticity and active coping behaviour in mice. Additionally, 2-Br-LSD reverses the effects of chronic stress. These findings suggest that 2-Br-LSD may have therapeutic potential for mood disorders and other indications.

2 Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms

This analysis of survey data (n=3364, Global Drug Survey 2020) finds a positive relationship between LSD and psilocybin use for self-treatment, and well-being outcomes, particularly insight and mood. A quarter of respondents reported adverse effects.

3 Association between mystical-type experiences under psychedelics and improvements in well-being or mental health

This review (s=44) synthesizes the evidence for the association between mystical-type experiences and improvements in well-being and mental health. It finds the strongest evidence in cross-sectional studies and healthy people. Some studies suggest that psychological insight and emotional breakthroughs may be similarly or more closely associated with positive changes than mystical-type experiences.

€15.00 / month

Researcher | Sprout Membership

Help support Blossom and get access to our full summaries & reports!

1 Vital*

Hybrid | 12 months | starting April 17th

Vital Psychedelic Training by Psychedelics Today is a 12-month professional certificate training program covering the elements of psychedelic therapy and integration, beginning again in April 2023.

2 Start2Finish DIY Psychedelic Integration Circle

Online | 9 weeks | enrolment opens March 20th

Start2Finish DIY Psychedelic Integration Circle: Workshop & Leadership Course by Altered States Integration gives anyone the skills needed to create community around psychedelics through providing integration support groups.

1 Exploring the Challenges of Psychedelic Integration | Lucid News

Psychedelic experiences can often be life-changing and transformative. But these experiences can also be challenging to integrate into daily life. They can bring about feelings of anxiety, confusion, and existential crisis.

To face this shadow side of psychedelics, I spoke with Anna Lutkajtis and Jules Evans about their recent research into the challenges of integrating psychedelic experiences.

2 Psychedelic Research Links March 2023

All the other papers that have come out this month we didn't add to the database.

1 Breaking Convention

Hybrid | 20 - 22 April

The 6th Breaking Convention takes place in the UK on 20-22 April 2023. Breaking Convention is Europe's largest conference on psychedelic consciousness and is now in its eleventh year.

2 INSIGHT 2023

Hybrid | 31 Aug - 3 Sep

The next edition of the INSIGHT Conference will take place take place in Berlin, Germany, from the 31st of Aug to the 3rd of Sep 2023.

3 Psychedelic Science

In-person | 19 - 25 June

Psychedelic Science 2023 is set to be the largest-ever psychedelic conference. The conference is being organized by MAPS and will take place in Denver, Colorado, in June 2023. The conference will cover all aspects of psychedelics and will be suitable for experts in the field who have no background knowledge of psychedelics.

Use code BLO15 for a 15% discount.

Check out PS2023

4 PhilaDelic

In-person | 13-15 June

The University of Pennsylvania is hosting the Philadelic Conference on the Interdisciplinary Frontiers of Psychedelics. The conference aims to bring together a diverse group of experts to advance the understanding of psychedelics through education, scholarship, and community.

*listed courses may provide an affiliate fee to Blossom

Floris from Blossom

I write about the science and implementation of psychedelics as medicines. Join to learn alongside me and make the future happen sooner!

Read more from Floris from Blossom

The Bloom #145 Free Edition catching up Welcome to all the new readers of The Bloom. This newsletter usually goes out every week, but due to several circumstances it's only hitting your inbox now. This means there is a lot to cover, and instead of the top 3 articles from last week, I've featured 8. Outside of the lab, two more psychedelic companies have received FDA Breakthrough Designation (a fast-track for review, like the one Lykos is currently in the final stages of). Cybin is developing...

about 4 hours ago • 6 min read

The Bloom #144 Free Edition increasing access Innovation and exploration continue to be the cornerstones of our journey at Blossom. This month, I'm thrilled to unveil a new way in which you can interact with our ever-expanding database of psychedelic research. Imagine a chat interface that not only understands your inquiries but is also backed by the full depth of our research database. This is not a distant dream but a reality we're alpha-testing right now. Discover the future of research...

23 days ago • 3 min read

The Bloom #143 Free Edition Unus pro Omnibus, Omnes pro Uno What can we learn from 10 years of PAT in a legal and reimbursed setting? Over 1000 patients have been treated in Switzerland since 2014, though challenges remain in the execution of PAT. One challenge is the question of whether we need to have repeated dosings. For clinical trials, it's standard to ... well ... standardize. But an innovative trial in Canada has studied the effects of doing repeated doses in some participants and...

about 1 month ago • 4 min read
Share this post